Semaglutide Dosing Schedule: A Complete Titration Guide

Semaglutide works best when the dose is built up gradually over several months. That is not a workaround or a limitation. It is the protocol the clinical trials were designed around, and the reason most people tolerate treatment well.

This guide explains the standard semaglutide titration schedule, why each step exists, how to handle complications along the way, and what long-term dosing looks like once you reach your maintenance phase.

*Compounded semaglutide is not FDA-approved. This article is for informational purposes only and does not constitute medical advice. Always follow the specific dosing instructions provided by your prescribing healthcare provider. Individual results vary.*

---

The Standard Semaglutide Dosing Schedule

The titration schedule for subcutaneous semaglutide follows a five-step progression over approximately 16 weeks. Each step lasts four weeks, giving your body time to adapt before the dose increases.

The 0.25 mg starting dose is not a therapeutic dose. It is there to prepare your digestive system for higher amounts. You are unlikely to see significant appetite suppression or weight loss during the first four weeks, and that is normal.

The 2.4 mg maintenance dose is where efficacy peaks. The landmark STEP 1 trial published in the *New England Journal of Medicine* showed a mean body weight reduction of 14.9% with 2.4 mg over 68 weeks, compared to 2.4% with placebo. ([PMID: 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185))

---

Why Titration Starts So Low

GLP-1 receptor agonists like semaglutide slow gastric emptying and act on the brain's appetite centers. At higher doses, these effects can cause significant nausea, vomiting, and GI discomfort, especially in the first few weeks.

Starting low lets your gut and brain adapt gradually rather than all at once.

A pooled analysis of the STEP 1 through 3 trials ([PMID: 34514682](https://pubmed.ncbi.nlm.nih.gov/34514682)) found that 43.9% of participants on semaglutide reported nausea, compared to 16.1% on placebo. However, 98.1% of GI side effects were mild to moderate in severity, and most occurred during or shortly after dose escalations, not at steady state.

A 2025 randomized controlled trial by Eldor et al. ([PMID: 40673973](https://pubmed.ncbi.nlm.nih.gov/40673973)) took this further, directly comparing a 16-week flexible titration against the standard 8-week schedule. The results were striking: only 2% of patients in the flexible titration arm discontinued due to GI adverse events, compared to 19% in the standard arm. The flexible group also reported significantly less nausea (45.1% versus 64.2%) without any meaningful loss in efficacy.

The clinical takeaway is clear: slower titration is not weakness. It is strategy.

---

When to Stay at a Lower Dose Longer

Your provider may recommend staying at your current dose for an additional four weeks before escalating. This is called an extended titration, and it is common.

You should let your provider know if you experience any of the following at your current dose:

• Nausea that disrupts normal eating or daily activities
• Vomiting more than once or twice per week
• Diarrhea or abdominal cramping that is difficult to manage
• Persistent fatigue or weakness that feels unusual
• Significant dehydration (dark urine, dizziness, reduced urination)

None of these mean the medication is not working for you. They mean your body needs more time at the current level. Delaying escalation preserves the long-term benefit while reducing the likelihood you will discontinue entirely.

Dose escalation should always follow tolerability, not just a calendar.

---

Missed Doses: What to Do

Semaglutide is taken once weekly, and it has a long half-life (approximately one week in circulation). Missing a single dose is not a medical emergency, but how you respond depends on timing.

If you are more than 48 hours away from your next scheduled dose: Take the missed dose as soon as you remember, then continue your regular weekly schedule.

If your next scheduled dose is within 48 hours: Skip the missed dose entirely. Do not double up. Take your next dose on the regularly scheduled day.

If you have missed two or more consecutive doses: Contact your provider before resuming. After a break of two or more weeks, your body may need to re-adapt, and some providers recommend restarting at a lower dose and titrating back up to minimize side effects on restart.

---

Not Everyone Reaches 2.4 mg

The 2.4 mg maintenance dose is the target in the clinical protocols, but it is not a strict requirement for meaningful results.

Some patients achieve significant weight loss at 1.0 mg or 1.7 mg and maintain it comfortably there. Others reach 2.4 mg and find the tolerability acceptable. Your maintenance dose is the highest dose your body tolerates well while producing meaningful clinical benefit. That will look different from person to person.

The STEP 5 trial ([PMID: 36216945](https://pubmed.ncbi.nlm.nih.gov/36216945)) followed participants for two years and found sustained mean weight loss of 15.2% with semaglutide, confirming that long-term efficacy holds at the full maintenance dose for most patients who can tolerate it.

---

What Happens If You Stop

This is worth understanding before you start.

The STEP 1 trial extension ([PMID: 35441470](https://pubmed.ncbi.nlm.nih.gov/35441470)) tracked participants for one year after they stopped semaglutide at the end of the 68-week trial. Patients regained approximately two-thirds of the weight they had lost within 52 weeks of discontinuation. Their metabolic markers, including blood pressure and blood sugar, also returned toward baseline.

This does not mean semaglutide is a lifelong requirement for everyone. But it does explain why treatment decisions, including how and when to taper, should be made with your provider and based on your individual health goals, not on a general timeline.

---

Keeping Your Injection Day Consistent

One practical detail that helps with tolerability: keep your injection day consistent from week to week.

Semaglutide's pharmacokinetics are designed around a steady seven-day interval. Drifting your injection day forward or backward by a day or two occasionally is not clinically significant, but chronic inconsistency can create peaks and troughs in blood levels that amplify side effects.

Choose a day that fits your routine. Many people pick a weekend morning when they have time to take the injection slowly, monitor how they feel, and adjust meals accordingly.

---

Dosing and Injection: A Quick Reference

For subcutaneous injections using a vial and syringe (the typical format for compounded semaglutide), dose conversion from milligrams to units on an insulin syringe depends on your vial's concentration. Your pharmacy will provide the specific unit conversion for your formulation.

Common compounded concentrations include:

• 1 mg/mL (lower concentration, used during early titration)
• 2.5 mg/mL
• 5 mg/mL (higher concentration, used at maintenance doses)

Always confirm the concentration printed on your vial before drawing your dose. The dose in milligrams stays the same across concentrations; the volume you draw changes.

If you are new to self-injection, see the [step-by-step injection guide](/articles/how-to-inject-semaglutide) for detailed technique instructions.

---

Summary: The Dosing Schedule at a Glance

• Start at 0.25 mg for weeks 1 through 4. This is an introductory dose, not a therapeutic one.
• Escalate every four weeks, moving through 0.5 mg, 1.0 mg, and 1.7 mg before reaching the 2.4 mg maintenance target.
• Stay longer at any dose if you are experiencing side effects. Four to eight extra weeks at a step is clinically appropriate and protects long-term adherence.
• Do not double up if you miss a dose. Skip it and return to your regular schedule, or contact your provider if you have missed more than two weeks.
• Not everyone reaches 2.4 mg, and that is acceptable. Your therapeutic dose is the one you tolerate and benefit from.
• Stopping suddenly is not dangerous, but expect some weight and metabolic marker changes over the following months.

Your provider and your pharmacy are your primary resources for any dosing questions specific to your situation. This guide is intended to give you context, not to replace their instructions.

*This article is for educational purposes only and does not constitute medical advice. Compounded semaglutide is not FDA-approved and is not equivalent to branded formulations. Always follow your prescribing provider's specific dosing instructions. Individual results vary significantly.*

*All medical services, including prescribing and dose titration decisions, are provided by independently licensed healthcare providers. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or make clinical decisions.*

*Clinical trial data cited in this article (STEP 1 through STEP 8, SUSTAIN 1) was generated with branded semaglutide formulations. Compounded semaglutide has not been studied in these trials, and outcomes with compounded formulations may differ.*

---

References

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med.* 2021;384(11):989-1002. [PMID: 33567185](https://pubmed.ncbi.nlm.nih.gov/33567185)

1. Sorli C, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). *Lancet Diabetes Endocrinol.* 2017. [PMID: 28110911](https://pubmed.ncbi.nlm.nih.gov/28110911)

1. Davies M, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). *Lancet.* 2021. [PMID: 33667417](https://pubmed.ncbi.nlm.nih.gov/33667417)

1. Rubino DM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. *JAMA.* 2021. [PMID: 33755728](https://pubmed.ncbi.nlm.nih.gov/33755728)

1. Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. *Nat Med.* 2022. [PMID: 36216945](https://pubmed.ncbi.nlm.nih.gov/36216945)

1. Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). *JAMA.* 2021. [PMID: 33625476](https://pubmed.ncbi.nlm.nih.gov/33625476)

1. Rubino D, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity (STEP 8). *JAMA.* 2022. [PMID: 35015037](https://pubmed.ncbi.nlm.nih.gov/35015037)

1. Wharton S, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. *Diabetes Obes Metab.* 2022;24(1):94-105. [PMID: 34514682](https://pubmed.ncbi.nlm.nih.gov/34514682)

1. Eldor R, et al. Gradual titration of semaglutide results in better treatment adherence and fewer adverse events. *Diabetes Care.* 2025. [PMID: 40673973](https://pubmed.ncbi.nlm.nih.gov/40673973)

1. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. *Diabetes Obes Metab.* 2022. [PMID: 35441470](https://pubmed.ncbi.nlm.nih.gov/35441470)